Daratumumab proves safe and highly effective in AL amyloidosis.
…, HD Liu, MA Karam, J Reed, S Mathur… - British Journal of …, 2019 - search.ebscohost.com
The article offers information on the Daratumumab (DARA), a first in class anti-CD38 human
antibody (IgG1j) with efficacy in relapsed multiple myeloma (MM) as monotherapy and in …
antibody (IgG1j) with efficacy in relapsed multiple myeloma (MM) as monotherapy and in …
[HTML][HTML] Safety, tolerability and efficacy of Cael-101 in AL amyloidosis patients treated on a phase 2, open-label, dose selection study to evaluate the safety and …
…, ON Koc, BM Faiman, K Hamilton, S Mathur… - Blood, 2020 - Elsevier
Background: CAEL-101 is an AL amyloid fibril reactive IgG1 monoclonal antibody with potential
for therapeutic immune clearance of AL amyloid deposits in AL amyloidosis (AL) patients…
for therapeutic immune clearance of AL amyloid deposits in AL amyloidosis (AL) patients…
Rapid hematologic and organ responses with daratumumab, bortezomib and dexamethasone in patients with relapsed/refractory AL amyloidosis
…, MA Karam, J Reed, BM Faiman, K Hamilton, S Mathur… - Blood, 2018 - ashpublications.org
Introduction: Multi-organ dysfunction remains a major cause of morbidity and mortality with
light chain amyloidosis (AL) especially for patients not achieving hematologic complete …
light chain amyloidosis (AL) especially for patients not achieving hematologic complete …
The Significance of a “MGUS” Tumor Board
…, J Khouri, LS Williams, BM Faiman, S Mathur… - Blood, 2023 - Elsevier
Our large academic medical center consists of both a main campus and several regional
sites that all offer hematology/oncology services where monoclonal gammopathy cases are …
sites that all offer hematology/oncology services where monoclonal gammopathy cases are …
[HTML][HTML] External validation of the impede VTE risk score in newly diagnosed Multiple Myeloma (MM) patients
…, BM Faiman, J Reed, MA Karam, K Schlueter, S Mathur… - Blood, 2019 - Elsevier
Background: Venous thromboembolism (VTE) is a prevalent cause of morbidity in MM
patients. The IMPEDE VTE score was recently proposed by Sanfilippo KM et al. in 2018 ASH …
patients. The IMPEDE VTE score was recently proposed by Sanfilippo KM et al. in 2018 ASH …
NS-62: The Importance of regular disease monitoring for patients with low or low intermediate risk Monoclonal Gammopathy of Undetermined Significance (MGUS)
B Faiman, J Khouri, H Kim, S Mathur, C Scott… - … Myeloma and Leukemia, 2021 - Elsevier
Background Monoclonal gammopathies encompass a number of disorders characterized by
a clone of a normal protein. Although biologically heterogeneous, monoclonal gammopathy …
a clone of a normal protein. Although biologically heterogeneous, monoclonal gammopathy …
Improving time to initiation of bone modifying agents in patients with newly diagnosed multiple myeloma.
…, CJ Samaras, AV Mejia, F Anwer, B Faiman, S Mathur… - 2019 - ascopubs.org
6528 Background: Current ASCO and IMWG guidelines recommend that all patients (pts)
on active anti-myeloma therapy receive concurrent supportive care treatment with a bone …
on active anti-myeloma therapy receive concurrent supportive care treatment with a bone …
Improving time to start bone modifying agents in newly diagnosed multiple myeloma patients.
…, N Rosko, J Reed, MA Karam, B Faiman, S Mathur… - 2019 - ascopubs.org
65 Background: Current ASCO and IMWG guidelines recommend all patients (pts) on active
myeloma therapy receive concurrent supportive care with a bone modifying agent (BMA) to …
myeloma therapy receive concurrent supportive care with a bone modifying agent (BMA) to …
[CITATION][C] NS-005: The Cleveland Clinic Survivor Care Program Model for patients living with multiple myeloma and plasma cell disorders
B Faiman, C Scott, S Mathur, S Mazzoni… - … Myeloma and Leukemia, 2022 - Elsevier
[CITATION][C] P-145: The clinical significance of a “MGUS” tumor board
S Mazzoni, B Faiman, J Khouri, S Mathur… - … Myeloma and Leukemia, 2022 - Elsevier